G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-213-9835
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees84
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions
What is G1 Therapeutics' stock symbol?
G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."
How were G1 Therapeutics' earnings last quarter?
G1 Therapeutics Inc (NASDAQ:GTHX) issued its quarterly earnings data on Wednesday, August, 8th. The company reported ($0.64) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.01. View G1 Therapeutics' Earnings History.
When is G1 Therapeutics' next earnings date?
What price target have analysts set for GTHX?
8 brokerages have issued twelve-month price objectives for G1 Therapeutics' shares. Their predictions range from $41.00 to $80.00. On average, they anticipate G1 Therapeutics' share price to reach $66.00 in the next year. This suggests a possible upside of 358.3% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.
What is the consensus analysts' recommendation for G1 Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.
Has G1 Therapeutics been receiving favorable news coverage?
News headlines about GTHX stock have been trending somewhat positive recently, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. G1 Therapeutics earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future.
Who are some of G1 Therapeutics' key competitors?
Some companies that are related to G1 Therapeutics include Arena Pharmaceuticals (ARNA), Ironwood Pharmaceuticals (IRWD), Nabriva Therapeutics (NBRV), Madrigal Pharmaceuticals (MDGL), The Medicines (MDCO), AnaptysBio (ANAB), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN), Endocyte (ECYT), Endo International (ENDP), Enanta Pharmaceuticals (ENTA), Heron Therapeutics (HRTX), Xencor (XNCR), Arrowhead Pharmaceuticals (ARWR) and Zai Lab (ZLAB).
What other stocks do shareholders of G1 Therapeutics own?
Who are G1 Therapeutics' key executives?
G1 Therapeutics' management team includes the folowing people:
- Dr. Mark A. Velleca, CEO, Pres & Director (Age 55)
- Mr. Barclay A. Phillips, CFO, Sr. VP of Corp. Devel. & Sec. (Age 56)
- Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 59)
- Mr. Alexander D. Smith M.S., VP of Technical Operations
- Dr. Jay C. Strum, Chief Scientific Officer (Age 55)
When did G1 Therapeutics IPO?
(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
Who are G1 Therapeutics' major shareholders?
G1 Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), BlackRock Inc. (5.28%), Bank of New York Mellon Corp (2.92%), Hillhouse Capital Advisors Ltd. (2.55%), BB Biotech AG (1.81%) and Northern Trust Corp (0.76%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Clay Thorp, Cynthia Schwalm, Fredric N Eshelman, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Medimmune Ventures, Inc, Ra Capital Healthcare Fund Lp, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Institutional Ownership Trends for G1 Therapeutics.
Which institutional investors are selling G1 Therapeutics stock?
GTHX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Barclays PLC, MetLife Investment Advisors LLC, United Services Automobile Association, TD Asset Management Inc., New York State Common Retirement Fund, California Public Employees Retirement System and Virtus ETF Advisers LLC. Company insiders that have sold G1 Therapeutics company stock in the last year include Barclay A Phillips, Clay Thorp, Jay Strum, Jennifer K Moses, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Insider Buying and Selling for G1 Therapeutics.
Which institutional investors are buying G1 Therapeutics stock?
GTHX stock was acquired by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors Ltd., FMR LLC, BB Biotech AG, Rhenman & Partners Asset Management AB, BlackRock Inc., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP and Citigroup Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Clay Thorp, Cynthia Schwalm, Fredric N Eshelman, James S Hanson, John Demaree and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for G1 Therapeutics.
How do I buy shares of G1 Therapeutics?
Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is G1 Therapeutics' stock price today?
One share of GTHX stock can currently be purchased for approximately $14.40.
How big of a company is G1 Therapeutics?
G1 Therapeutics has a market capitalization of $535.54 million. The company earns $-85,290,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.
What is G1 Therapeutics' official website?
How can I contact G1 Therapeutics?
G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.
MarketBeat Community Rating for G1 Therapeutics (NASDAQ GTHX)
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
